Stock Events

CureVac N.V. 

€3
298
-€0.08-2.66% Today

Statistics

Day High
3.2
Day Low
3
52W High
-
52W Low
-
Volume
8,215
Avg. Volume
-
Mkt Cap
721.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15AugConfirmed
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Next
-0.34
-0.31
-0.27
-0.24
Expected EPS
-0.28446912072
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5CV.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap19.5B
BioNTech SE is a direct competitor in the mRNA technology space, focusing on developing vaccines and therapeutics, similar to CureVac's core business.
Moderna
MRNA
Mkt Cap33.28B
Moderna, Inc. is a leader in mRNA therapeutics and vaccines, directly competing with CureVac in the COVID-19 vaccine market and other therapeutic areas.
Pfizer
PFE
Mkt Cap172.43B
Pfizer Inc., in collaboration with BioNTech, competes in the mRNA vaccine market, particularly with their COVID-19 vaccine, which is in direct competition with CureVac's development.
Novavax
NVAX
Mkt Cap1.65B
Novavax, Inc. competes in the vaccine space, particularly with its protein-based COVID-19 vaccine, offering an alternative to mRNA vaccines like those developed by CureVac.
Johnson & Johnson
JNJ
Mkt Cap395.12B
Johnson & Johnson competes in the vaccine market with its viral vector COVID-19 vaccine, offering an alternative approach to CureVac's mRNA technology.
Astrazeneca
AZN
Mkt Cap253.65B
AstraZeneca PLC competes with its viral vector COVID-19 vaccine, which is a different technology but serves the same market as CureVac's vaccine candidates.
Sanofi
SNY
Mkt Cap134.6B
Sanofi competes in the vaccine and therapeutic market, working on mRNA vaccines and other technologies that could compete with CureVac's products.
GSK
GSK
Mkt Cap83.77B
GlaxoSmithKline plc competes in the vaccine space, including collaborations on COVID-19 vaccines and other therapeutic areas that overlap with CureVac's interests.
Arcturus Therapeutics
ARCT
Mkt Cap553.45M
Arcturus Therapeutics Holdings Inc. is involved in the development of mRNA vaccines and therapeutics, making it a direct competitor in the same technology space as CureVac.
Telesis Bio
TBIO
Mkt Cap9.26M
Translate Bio, now a part of Sanofi, focuses on mRNA technologies for vaccines and therapeutics, directly competing with CureVac in the mRNA space.

About

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Show more...
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Employees
999
Country
NL
ISIN
NL0015436031
WKN
000A2P71U

Listings